Avanza Fonder AB Acquires 21,210 Shares of Boston Scientific Corporation $BSX

Avanza Fonder AB boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 13.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 182,979 shares of the medical equipment provider’s stock after purchasing an additional 21,210 shares during the period. Avanza Fonder AB’s holdings in Boston Scientific were worth $17,447,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Steph & Co. bought a new stake in shares of Boston Scientific during the third quarter worth $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Finally, United Community Bank lifted its position in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $69.54 on Tuesday. The company has a market cap of $103.34 billion, a PE ratio of 35.84, a PEG ratio of 0.97 and a beta of 0.69. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 1 year low of $67.56 and a 1 year high of $109.50. The company’s 50-day moving average is $79.22 and its two-hundred day moving average is $91.68.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the company earned $0.70 EPS. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research reports. Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Citigroup decreased their price target on shares of Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Evercore dropped their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, Wells Fargo & Company reduced their price objective on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $106.27.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham & Company reiterated a “Buy” rating on BSX, reinforcing institutional support for the shares amid the post-earnings pullback; this helps underpin demand from investors looking for growth exposure in medical devices. Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Several market write-ups argue the pullback could be a buying opportunity given solid recent fundamentals (beat on adjusted EPS, strong free cash flow, growth in EP and Watchman) and potential catalysts such as Champion-AF trial results and the planned Penumbra acquisition — but these are contingent on upcoming clinical and integration outcomes. Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback?
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for a securities class action covering purchases between July 23, 2025 and Feb 3, 2026; they remind investors of a May 4, 2026 lead-plaintiff deadline — this increases legal overhang and potential litigation costs/settlement risk. ROSEN – Class Action Notice Robbins LLP – Class Action Alert Faruqi & Faruqi – Class Action Notice
• Negative Sentiment: MassDevice reports alleged long-running pacemaker battery problems — product reliability and potential recalls or regulatory scrutiny could materially affect device sales and margins if issues are confirmed and widespread. Boston Scientific has reportedly had pacemaker battery problems for years
• Negative Sentiment: Stifel cut its price target on BSX to $90, signaling some analyst caution and reduced near-term upside expectations even where ratings remain constructive — this can weigh on sentiment and caps potential rebound momentum. Stifel Nicolaus Cuts Boston Scientific Price Target to $90

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.